Thomas Butler is the founder of Biomea Fusion. Biomea Fusion has raised $350M in total funding. Latest round: Series A. Based in Redwood City, California.
Thomas Butler is the Co-founder and Chief Executive Officer of BioRevolution. Prior to this, he co-founded Biomea Fusion in 2018, serving as CEO and Chairman. Biomea Fusion developed into a fully integrated drug discovery and development organization, going public in 2021 and reaching a market capitalization of over $1.5 billion in 2023. The company raised $350 million across three funding rounds. Earlier, he was Head of Investor Relations at Pharmacyclics and a medicinal chemist at Gilead Sciences, where he co-invented VEKLURY® (Remdesivir).
Full founder directory · Investor directory · Company funding database · Fundraising library